2021 CERVICAL CANCER ELIMINATION PROGRESS REPORT:

Australia’s progress towards the elimination of cervical cancer as a public health problem

Prepared by the NHMRC Centre of Research Excellence in Cervical Cancer Control
This report was prepared by members of the NHMRC Centre of Research Excellence in Cervical Cancer Control:
Julia Brotherton, Dorothy Machalek, Megan Smith, Susan Yuill, Maddison Sherrah, Lisa Whop, Sue Evans, Deborah Bateson, Helen Marshall, Suzanne Garland, David Hawkes, David Wrede, Rebecca Guy, Claire Nightingale, John Kaldor, Marion Saville and Karen Canfell


Contact details
https://www.cervicalcancercontrol.org.au

For any enquiries about this report or the work of the CRE, please email Ms Tracey McDermott, Research and Administrative Support, NHMRC C4 Centre of Research Excellence in Cervical Cancer Control at admin@cervicalcancercontrol.org.au

Acknowledgements
We would like to acknowledge the support of the Department of Health and the enthusiasm and encouragement of key stakeholders in cervical cancer prevention and control throughout Australia in supporting the need for and development of this report.

We particularly acknowledge the work of the Cancer Screening Section of the Australian Institute of Health and Welfare, in particular Alison Budd and Fan Xiang, and the work of the National Centre for Immunisation Research and Surveillance, particularly Alexandra Hendry, Frank Beard, Aditi Dey and Brynley Hull, in preparing data for this report. We are fortunate to work in a community with such skilled and generous colleagues to support timely sharing of information to support public health.

We also thank Luke Cuell for developing the timeline graphic and Tracey McDermott for her assistance with the preparation of this report.

We hope these reports will help harness the political will, community support and our available resources to ensure elimination is achieved and that equity in outcomes for all remains front of mind. We look forward to a time in the near future when the report documents Australia’s achievement of the elimination of cervical cancer as a public health problem.

C4 acknowledges the people and the Elders of the Aboriginal and Torres Strait Islander Nations who are the Traditional Owners of the lands and seas of Australia

TABLE OF CONTENTS

PREFACE 2
EXECUTIVE SUMMARY 4
DISEASE OUTCOME INDICATORS 8
Indicator 1 – Cervical cancer incidence 8
Indicator 2 – Cervical cancer mortality 10
Indicator 3 – Detection of high-grade cervical disease 12
Indicator 4 – Prevalence of HPV infection 16
VACCINE COVERAGE INDICATORS 19
Indicator 5 – HPV vaccine completion by age 15 years 19
Indicator 6 – HPV vaccine initiation by age 15 years 21
SCREENING PARTICIPATION INDICATORS 24
Indicator 7 – Screening participation by age 35 and 45 years 24
Indicator 8 – Screening participation (Australian program) 26
TREATMENT UPTAKE INDICATORS 28
Indicator 9 – Colposcopy attendance 28
Indicator 10 – High-grade cervical disease treatment rates 30
Indicator 11 – Cervical cancer treatment rates 31
REFERENCES 35

ABBREVIATIONS USED IN THIS REPORT
ABS: Australian Bureau of Statistics; AIHW: Australian Institute of Health and Welfare; AIR: Australian Immunisation Register; AIS: adenocarcinoma in situ; C4: the NHMRC Centre of Research Excellence in Cervical Cancer Control; CIN: cervical intraepithelial neoplasia; Compass: the Compass trial, a randomised trial of over 76,000 women comparing HPV vs cytology based screening in Australia; HPV: human papillomavirus; MBS/PBS: Medicare Benefits Schedule/Pharmaceutical Benefits Scheme; NCSP: National Cervical Screening Program; NCSR: National Cancer Screening Register; NCIRS: National Centre for Immunisation Research and Surveillance; NHMRC: National Health and Medical Research Council; OR: odds ratio; WHO: World Health Organization; standard abbreviations for Australia’s eight States and Territories (NSW, Vic, Qld, NT, SA, WA, Tas, ACT)
In November 2020, following two years of consultation and development, WHO formally launched the ‘Global strategy to accelerate the elimination of cervical cancer as a public health problem’1. The strategy provides a pathway to the global elimination of cervical cancer as a public health problem (target incidence of <4 per 100,000 within a century. It has been made possible by advances in the understanding of cervical cancer as a preventable cancer caused by oncogenic human papillomavirus (HPV) and new technology that can be implemented at the population level enabling 1) primary prevention through HPV vaccination and 2) more effective and accessible secondary prevention through HPV-based cervical screening, in the context of 3) effective treatment modalities being established for cervical precancer and early-stage invasive cancer. When vaccination and screening is combined with timely diagnosis and treatment services for cervical cancer, the end to the enormous global suffering caused by the fourth most common female cancer with a disproportionate burden in lower income settings, will finally be in reach. Under the WHO strategy, countries are invited to commit to achieving coverage targets by 2030 in the implementation of strategies for primary and secondary prevention in the context of comprehensive cancer treatment. These so-called ‘90/70/90’ targets are:

1. 90% of girls fully vaccinated with HPV vaccine by age 15
2. 70%+ of women screened with a high-performance test (such as HPV) by age 35 and again by 45
3. 90% of women with screen-detected precancer and 90%+ of women with cervical cancer treated

Australia is a long-standing world leader in cervical cancer prevention and control, having achieved a halving of incidence and mortality through the cytology-based National Cervical Screening Program first implemented in 1991 (see Box for timeline); and the world’s first national HPV vaccination program in 2007 (see Box for timeline), which has seen rates of HPV infection and cervical precancer lesions plummet. With the transition from cytology to HPV based screening in December 2017 (projected to further reduce cervical cancer incidence rates by 20-30%) and the introduction of the nonavalent HPV vaccine in 2018 (protection against ~90% of cancer-causing HPV types), Australia is expected to be the first country to achieve WHO’s definition of cervical cancer elimination as a public health problem, potentially as early as 2028.

Australia has also been a world leader in research and surveillance documenting the impact of control programs for cervical cancer. Since 2018, Australian public health and clinical researchers have been collaborating in the NHMRC-funded Centre of Research Excellence in Cervical Cancer Control (C4). Partners include many investigators who have been collecting, analysing and reporting key epidemiological information about the occurrence of cervical cancer and its precursors. The resources of C4 and its partner organisations have been used in consultation with key stakeholders, to deliver this comprehensive report, planned to be the first in a regular series, on Australia’s progress towards the elimination of cervical cancer as a public health problem. The report is based on 11 key indicators grouped into 4 components (see Table 1) framed by the WHO ‘90/70/90’ 2030 scale up targets for elimination, derived from the most recently available data. Twin goals of the report are to monitor progress towards achievement of targets and to provide recommendations for improving the quality, availability and timeliness of indicator data.

1) Cervical cancer incidence
2) Cervical cancer mortality
3) Detection of high-grade cervical disease
4) Prevalence of HPV infection
5) HPV vaccine completion by age 15
6) HPV vaccine initiation by age 15
7) Screening participation
8) Screening participation (Australian program)
9) Cervical cancer treatment rates
10) High-grade cervical disease treatment rates

ITALICS INDICATE THAT THESE ARE THE WHO 2030 SCALE UP INDICATORS

Reducing cancer incidence and mortality are the goals of cervical cancer control programs. High-grade cervical disease is the precursor to cancer, preventable by vaccination and prevented and detected through screening and precancer treatment. HPV infection is preventable by vaccination and changes in prevalence are detectable earlier than falls in high-grade cervical disease or cancer.

These indicators monitor the ongoing implementation and reach of the vaccine program. Coverage by age 15 is the standard measure recommended by WHO to allow comparisons over time and between populations, given that the routine age at vaccination is variable but recommended between the ages of 9 and 14 years.

These indicators monitor the implementation and reach of the cervical screening program, taking into account Australia’s recent transition from a 2-year screening interval under the previous cytology-based program to a 5-year interval in the HPV based program.

These indicators monitor the rate at which women reach further assessment following a positive screening test and rates of treatment for high-grade cervical disease and cancer.

ITALICS INDICATE THE WHO 2030 SCALE UP INDICATORS

The resources of C4 and its partner organisations have been used in consultation with key stakeholders, to deliver this comprehensive report, planned to be the first in a regular series, on Australia’s progress towards the elimination of cervical cancer as a public health problem. The report is based on 11 key indicators grouped into 4 components (see Table 1) framed by the WHO ‘90/70/90’ 2030 scale up targets for elimination, derived from the most recently available data. Twin goals of the report are to monitor progress towards achievement of targets and to provide recommendations for improving the quality, availability and timeliness of indicator data.
EXECUTIVE SUMMARY

In this first data audit of Australia’s progress towards the elimination of cervical cancer as a public health problem, we have brought together the most recent data available across 11 indicators to paint a snapshot of our current status. In doing so we have not only identified how far we have come in cervical cancer prevention and control in Australia but additionally how much work there is still left to do, both in terms of public health action and necessary improvements in the way we gather and synthesise data to inform these actions.

THE INDICATORS: WHERE ARE WE NOW?

Disease outcomes
The first four indicators cover disease outcomes including the target for elimination (incidence below 4 per 100,000 women). Indicator 1 Cervical cancer incidence and Indicator 2 Cervical cancer mortality are low by global standards (6.3 per 100,000 in 2011-2015 and 1.4 per 100,000 in 2014-2018) but substantial inequities remain, with the incidence rate in non-Indigenous women just below the threshold defining a rare cancer (at 5.7 per 100,000 in 2011-2015), whereas the incidence rate for Indigenous women was more than twice as high (at 12.1 per 100,000). Mortality rates were over three times higher in Indigenous women. In the final year of the cytology-based screening program (2017), the rate of Indicator 3 Detection of high-grade cervical disease (the precursor of cervical cancer detected through screening) was 7.1 per 1,000 women screened. This rate has been falling due to the downward trend in disease rates in young women following the HPV vaccination program. Indicator 4 Prevalence of HPV infection also documents the success of the HPV vaccination program, with HPV16 or 18 (the most serious cancer-causing types of HPV and prevented by vaccination) detected in only 2.0% of screened women across age groups, socioeconomic groups, remoteness areas and jurisdictions. Other cancer-causing types were detected in 6.5% of screened women.

HPV vaccination
The next two indicators monitor delivery of the HPV vaccine at a benchmark age by which adolescents have had the opportunity to be vaccinated. Indicator 5 HPV vaccine completion by age 15 found that 78.2% of 15 year olds in 2019 had completed the course (79.6% of females and 76.8% of males), with Indigenous adolescents having a lower completion rate of 68.5% (female 71.4%, male 65.4%). In contrast Indicator 6 HPV vaccine initiation by age 15 found equal coverage by Indigenous status (66.0% in Indigenous, 86.4% in non-Indigenous adolescents), with Indigenous females in NSW, the NT and Victoria the only groups with over 90% dose 1 coverage. HPV vaccination appears to be more equitably delivered than cervical screening and is at close to the rate predicted to be required for eventual elimination of vaccine preventable HPV types in a both-sex vaccination program (80%), although below the 90% WHO target for girls.

Screening participation
Two indicators monitor screening participation, with Indicator 7 Screening participation by age 35 and 45 years enabling assessment directly against the WHO scale up target for 2030 of 70% for the globally recommended minimum target of two screens with a high precision test (HPV test or better) in a lifetime. By age 35 in 2019, 54.9% of women had had an HPV test, with the same percentage having had an HPV test by age 45 and a previous cytology screen in the preceding 10 years. Women in the NT and very remote areas had lower participation. Indicator 8 Screening participation, Australian program monitors participation against the national program recommendations, with 52.4% of Australian women up to date with recommended screening by the end of 2019, two years into the renewed screening program, but inequalities in participation were apparent by socioeconomic status and area of residence.

Treatment
The final three indicators relate to the third pillar of the elimination strategy which is treatment. Indicator 9 Colposcopy attendance suggested, within the limitations of likely under-reporting, that most women do eventually have a colposcopy when indicated on the basis of their screening result (87.8% by 15 months for women referred in 2018) but that some women experienced suboptimal timeliness, with 68.8% of women having a colposcopy within three months, with variation by geography and socioeconomic status. Data for Indicator 10 High-grade cervical disease treatment rates, which will measure directly against the WHO scale up target of 90% of women receiving treatment, could not be reported due to a lack of available data at this time (this indicator requires comprehensive histopathology and treatment data from colposcopy reports). Similarly, limited data was available for Indicator 11 Cervical cancer treatment rates, with no national data available to assess against the WHO scale up target of 90% treatment. Queensland data from 2011-2014 indicated a treatment rate of 94% in metropolitan and regional areas and 92% in rural and remote areas. Two small studies suggested some potential underuse of chemotherapy and radiotherapy historically at one centre and that Indigenous women may be more likely to receive suboptimal treatment.

Data issues
Timeliness is an issue for both cancer incidence data and screening data, with no robust data available for the new program to determine rates of high-grade cervical disease since the move to HPV-based screening. The 4-5 year lag nationally in cancer incidence reporting has meant it is still unclear whether as predicted by modelling9, HPV vaccination is already impacting cervical cancer rates in young women, whereas Sweden has already documented this impact with a population smaller than Australia’s with timely linked data10. HPV vaccination data reporting was also delayed following the integration of HPV vaccine doses into the Australian Immunisation Register but should now be included in routine coverage reports.

For the cervical screening related indicators, we were unable to report outcomes by Indigenous status. This remains a critical data gap, given the persisting higher incidence and mortality from cervical cancer amongst Indigenous Australians. Despite national indicators designed to ensure quality, safety and effectiveness of the program, only cervical incidence and mortality data have been reported by Indigenous status over the life of the program, derived from State and Territory cancer registries rather than cervical screening program data. Estimates of participation in the program and screening outcomes for Indigenous Australians have relied on data collection at the local level and data linkage studies, which have provided some estimates but an incomplete picture of the national situation. The move to a national registry system and program change to support the renewed program provided a tangible opportunity to correct this long-standing data deficiency. Three years into the renewed program, data are still unable to be reported by Indigenous status. However, by the next report a more complete picture should be available, with consultation underway in 2021 to endorse a proposed methodology for reporting Indigenous status as held by the National Cancer Screening Register (NCSR). Such a methodology is likely necessary, given Indigenous status is under-reported to Medicare with variation by age group, gender and jurisdiction and, for last reported Indigenous status, 28% of screening participants recorded ‘not stated’ on the NCSR (Table A1.6, 2020 AHW monitoring report10). Longstanding systemic barriers to the collection and reporting of Indigenous status need to be overcome, whilst also acknowledging the barriers experienced by many Indigenous Australians to self-disclosure of their Indigenous identity given the history of colonisation and intergenerational trauma.

Please note throughout this report we generally use the term ‘women’ to refer to people eligible for attending cervical screening or experiencing cervical cancer. However, we respectfully acknowledge that some people with a cervix do not identify as women and are equally impacted by the risk of cervical cancer.
**Recommendations**

That persisting inequities in vaccination course completion and screening participation for Indigenous Australians are addressed by making reducing these inequalities a clear policy priority in the programs, addressing system level barriers to recording Indigenous status and by working with Indigenous Australians to develop and lead culturally appropriate solutions.

That data collection and availability are improved for those indicators for which we were unable to provide current estimates. In particular, the completeness of colposcopy and histopathology data within the cervical screening program should be a major focus and necessary steps taken to maximise the timely collection of accurate data through standardised coding, electronic data capture, strong engagement with service providers and prioritisation of these outcome data. Action to improve the timeliness of national cancer incidence data is also necessary if Australia wishes to know in close to real time when elimination has been achieved.

That a methodology is developed to monitor cervical cancer treatment rates. Likely challenges include the lack of routinely collected staging data, timeliness of cancer registry data, linking treatment related datasets and the complexity of assessing patient care against optimal care benchmarks in order to clarify whether there are existing inequities in access that require addressing. The emerging clinical quality registry for gynaecological cancers may have a role to play in addressing the need to monitor treatment in future.

We are optimistic that Australia can address the challenges identified in this first report and hope that this report can help inform a national strategy to ensure Australia’s progress towards the elimination of cervical cancer as a public health problem is on-track for all women.

---

**EXECUTIVE SUMMARY (cont.)**

**AUSTRALIA’S PROGRESS TOWARDS CERVICAL CANCER ELIMINATION AGAINST WHO TARGETS**

<table>
<thead>
<tr>
<th>INDICATOR</th>
<th>WHO TARGET</th>
<th>STATUS IN 2020 REPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical cancer incidence</td>
<td>Fewer than 4 new cases per 100,000</td>
<td>6.3 new cases per 100,000 (2011–2015). Rates were at least twice as high as the elimination target in Indigenous women, and women living in remote or very remote areas</td>
</tr>
<tr>
<td>HPV vaccine coverage by 2030</td>
<td>90% of girls fully vaccinated by the age of 15 years*</td>
<td>Completed course coverage was 78.2% by 15 years in 2019 (79.6% in females and 76.8% in males). It was lower amongst Indigenous adolescents (68.5% overall, 71.6% in females and 65.4% in males)</td>
</tr>
<tr>
<td>Screening participation by 2030</td>
<td>70% of women screened using a high-performance test* by age 35 years and again by age 45 years</td>
<td>54.9% of women aged 35 had been screened at least once with an HPV test by end 2019. HPV screening has not been available long enough for women to have had two high-performance tests by age 45</td>
</tr>
<tr>
<td>Treatment of cervical precancer by 2030</td>
<td>90% of women with identified precancer are treated</td>
<td>No routine data available to support this indicator</td>
</tr>
<tr>
<td>Treatment of cervical cancer by 2030</td>
<td>Management of 90% of women with invasive cervical cancer</td>
<td>No national data available. Queensland data (2011–2014) show 94% of women in metropolitan/ regional areas were treated and 92% in rural/remote areas</td>
</tr>
</tbody>
</table>

* This target applies to girls only programs, which are the most cost-effective option for countries to achieve elimination, where very high coverage is necessary. Modeling has suggested, for countries that have introduced both-sex vaccination, that elimination of vaccine-preventable types is likely achievable with 80% coverage.

# A high-performance test refers to a test with performance characteristics at least as good as the HPV test.
INDICATOR 1 – CERVICAL CANCER INCIDENCE

Rationale
Cervical cancer incidence is the measure used by the WHO to determine whether elimination has been achieved.

Status of indicator
WHO target: Fewer than 4 new cases per 100,000
Status: Cervical cancer incidence was 6.3 per 100,000 in 2011-2015 (most recent data available), so a 37% reduction is required to reach elimination. Rates were at least twice as high as the elimination target in women living in remote or very remote areas. Incidence rates increased with increasing levels of socioeconomic disadvantage. Further 37% reduction from current rates is needed to achieve elimination at the national level; in Indigenous women, a 67% reduction is required to reach the elimination target.

In 2015, 821 women were diagnosed with cervical cancer in Australia. Nationally, cervical cancer incidence was 6.3 per 100,000 in 2011-2015 (Figure 1.1). Incidence varied between groups, and rates were three times as high as the elimination target in Indigenous women, and at least twice as high as the elimination target in women living in remote or very remote areas. There is a socioeconomic gradient in cervical cancer incidence, with the incidence rates becoming higher with increasing levels of socioeconomic disadvantage. A further 37% reduction from current rates is needed to achieve elimination at the national level; in Indigenous women, a 67% reduction is required to reach the elimination target.

Figure 1.1 – Cervical cancer incidence (2011-2015), per 100,000 females

Notes on methods

In order to report on cancer incidence across a range of population groups, data are reported across a 5-year period. Results by Indigenous status are based on four jurisdictions (NSW, Qld, WA and NT) where data quality was considered sufficient for analysis. Cervical cancer incidence reported here is based on age-specific rates published in AIHW reports. Age-standardised rates are lower than in the AIHW report, because the age-standardising method and standard population recommended by WHO for measuring cervical cancer elimination has been used, to enable comparison with the WHO target and internationally. Age-specific rates were not published when they were non-zero and based on a cell size that was less than five; for this reason, rates for TAS, ACT and NT are based on imputed cases or an assumption there were 2.5 cases in some age groups. In addition to this, rates for the ACT and NT are based on fewer than 100 cases over a 5-year period.

Interpretation, issues and challenges for this indicator
There is currently a delay of four to five years in the availability of national cancer incidence data in Australia, which limits our ability to conduct timely reporting of cervical cancer incidence in Australia against the primary WHO elimination target. More timely data have been published for Victoria, but did not include age-specific rates (which are required in order to compare against the WHO target). These Victorian data to 2019 suggest cancer incidence is lower in women aged less than 25 than in the pre-vaccination period. A transient increase in cancer diagnoses is expected in future (from around 2018), as a result of Australia transitioning from 2-yearly cytology-based screening to 5-yearly primary HPV screening, which occurred on 1st December 2017. This anticipated increase would be due to the more sensitive screening test leading to the detection of some prevalent cancers and will represent a success of the new program (given that earlier detection leads to downstaging of cancer and improved survival).
INDICATOR 2 – CERVICAL CANCER MORTALITY

Rationale
Reducing premature mortality from cervical cancer is the overarching aim of the WHO elimination strategy, so cervical cancer mortality has been identified as a key impact indicator in the global strategy to accelerate elimination. Cervical cancer mortality will capture two things that will not be reflected in cervical cancer incidence rates: downstaging (due to screening) and the WHO target of treating 90% of women diagnosed with cervical cancer.

Status of indicator
WHO target: no target set
Status: Cervical cancer mortality was 1.4 per 100,000 women in the period 2014-2018 (most recent data), with an inverse socioeconomic gradient, and rates over three times as high in Indigenous women (3.5x) and very remote areas (3.0x), and twice as high in the NT.

In 2018, there were 232 deaths from cervical cancer. Cervical cancer mortality was 1.4 per 100,000 women in 2014-2018 with some variation in mortality across the population, most notably higher rates for Indigenous women, women living in very remote areas, and women in the NT, and a socioeconomic gradient (Figure 2.1).

Notes on methods
In order to report on cancer mortality across a range of population groups, data are reported across a 5-year period (the most recent 5-year period for which data are available). Age-specific rates were sourced from the most recent national report. Age-standardisation is performed across all ages using the 2015 World Population, consistent with the methodology recommended for incidence as part of the WHO elimination strategy. As a result of this difference in methodology, mortality rates in this report are not comparable to AIHW reports.

Interpretation, issues and challenges for this indicator
National mortality data are more timely than national cancer incidence data. Cervical cancer mortality is relatively low in many groups but many of the groups with higher rates correspond with those with a higher incidence (higher rates in Indigenous women and increasing rates with increasing level of socioeconomic disadvantage). There is considerable overlap in the groups identified as having the highest mortality rates (Indigenous women, women living in very remote areas, women living in the NT).

Reductions in cervical cancer mortality over time will reflect a range of factors, including improved prevention, earlier detection (downstaging), improvements to treatment, and providing more women with optimal treatment.
**DISEASE OUTCOME INDICATORS (Cont.)**

**INDICATOR 3 – DETECTION OF HIGH-GRADE CERVICAL DISEASE**

**Rationale**
Cervical screening aims to detect specific types of cervical disease (known as high-grade - see Methods below for details) that are considered to be the precursors of cervical cancer, so that women can have treatment to prevent progression to cancer.

This indicator measures the proportion of women screened who are found to have high-grade disease as defined by a positive result on biopsy. It will be determined by the underlying proportion with high-grade disease in the screened population, the accuracy of the screening method used, and the subsequent diagnostic steps and follow up undertaken with women found positive on the screening method.

**Status of indicator**

**WHO target:** no target set

**Status:** Nationally, detection of high-grade cervical disease in the pre-Renewal cytology-based program was 7.1 per 1,000 screened women aged 20-69 years between Jan-June 2017. For reference with the current primary HPV program, the crude rate for women aged 25-74 years in 2017 was 6.6 per 1,000 screened women. The rate was highest in the 25-29 year old age group at 14.4 per 1,000 screened women (Figure 3.1), and has declined steadily over time in women aged 20-34, since the introduction of HPV vaccination (12,13). (Figure 3.1) NT had the highest rate of detection. (Figure 3.2)

Breakdowns by Indigenous status, socioeconomic group and remoteness area were unavailable.

Nationally, detection of high-grade cervical disease in the pre-Renewal cytology-based program was 7.1 per 1,000 screened women aged 20-69 years between Jan-June 2017. For reference with the current primary HPV program, the crude rate for women aged 25-74 years in 2017 was 6.6 per 1,000 screened women. The rate was highest in the 25-29 year old age group at 14.4 per 1,000 screened women (Figure 3.1), and has declined steadily over time in women aged 20-34, since the introduction of HPV vaccination (12,13). (Figure 3.1) NT had the highest rate of detection. (Figure 3.2)

Breakdowns by Indigenous status, socioeconomic group and remoteness area were unavailable.

**Figure 3.1 – Rates of histologically confirmed high-grade cervical disease (Jan 2013–June 2017) by age group for women aged 20–69 years**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20–24</td>
<td>15.0</td>
<td>12.9</td>
<td>11.8</td>
<td>10.6</td>
<td>10.0</td>
</tr>
<tr>
<td>25–29</td>
<td>20.3</td>
<td>18.5</td>
<td>17.7</td>
<td>15.9</td>
<td>14.4</td>
</tr>
<tr>
<td>30–34</td>
<td>16.5</td>
<td>16.1</td>
<td>13.5</td>
<td>12.6</td>
<td>12.9</td>
</tr>
<tr>
<td>35–39</td>
<td>9.6</td>
<td>9.3</td>
<td>9.4</td>
<td>9.5</td>
<td>9.1</td>
</tr>
<tr>
<td>40–44</td>
<td>6.3</td>
<td>6.6</td>
<td>6.3</td>
<td>6.5</td>
<td>6.2</td>
</tr>
<tr>
<td>45–49</td>
<td>4.0</td>
<td>4.0</td>
<td>4.2</td>
<td>4.3</td>
<td>4.0</td>
</tr>
<tr>
<td>50–54</td>
<td>2.6</td>
<td>2.6</td>
<td>2.6</td>
<td>2.4</td>
<td>2.2</td>
</tr>
<tr>
<td>55–59</td>
<td>1.6</td>
<td>1.9</td>
<td>1.6</td>
<td>1.6</td>
<td>1.8</td>
</tr>
<tr>
<td>60–64</td>
<td>1.4</td>
<td>1.7</td>
<td>1.5</td>
<td>1.5</td>
<td>1.4</td>
</tr>
<tr>
<td>65–69</td>
<td>1.4</td>
<td>1.0</td>
<td>1.3</td>
<td>1.1</td>
<td>1.2</td>
</tr>
<tr>
<td>ALL 20–69 ASR</td>
<td>8.5</td>
<td>8.1</td>
<td>7.8</td>
<td>7.4</td>
<td>7.1</td>
</tr>
</tbody>
</table>

* ASR = age standardised rate
DISEASE OUTCOME INDICATORS (Cont.)

Notes on methods
Source: AIHW, Cervical screening in Australia 2019 data14. Women who had been offered HPV vaccination were aged 20-32 in 2013, and 20-36 in 2017. Data presented used the methodology of the AIHW Cervical Screening in Australia reports for the former NCSP14. High-grade cervical disease was defined as a histology result of HS03 (CIN NOS, CIN II and CIN III) or HE03 (endocervical dysplasia and adenocarcinoma in situ). Age-standardised rates were the number of women with a high-grade abnormality detected by histology per 1,000 women screened, age-standardised to the Australian 2001 Standard Population15. These data exclude women who had opted off the jurisdictional cervical screening registers.

Interpretation, issues and challenges for this indicator
Due to known substantial under-enumeration of histopathology reports in the currently available NCSR data set (with updated data pending), we used data from 2017 for this report. We were concerned that the large number of missing reports would significantly underestimate the true high-grade detection rate. The AIHW report using these data estimated a provisional rate of 8.6 per 1,000 women screened in 20193.

Following the transition in 2017 to primary HPV- based screening, which is known to be more sensitive than cytology for the detection of high-grade cervical abnormalities, an increase in detection rates for both pre-cancer and cancer was anticipated8. The pilot phase results of the Compass trial, which is comparing cytology-based and HPV-based screening in Australia and serves as a sentinel evaluation of the new screening program, confirmed a higher rate of high-grade detection in the HPV based screening arms than in the cytology arm16.

The available data demonstrate the impact of the HPV vaccination program on overall rates of high-grade cervical disease in Australia. Although national data were not available for inclusion in the report, previous research in Qld, the NT and SA has demonstrated that Indigenous women had higher rates of high-grade disease at screening than non-Indigenous women (about twice as high, although with a closing of this gap in the most recent period in the NT, the jurisdiction with the largest proportion of the population who are Indigenous17-19. Univariate analyses of national data indicated that women residing in the lowest socioeconomic quintile had higher rates than those in the highest and that women living in the remotest areas also had significantly higher rates detected20.

A particular challenge for this indicator is interpretation over time. Where the population effectively recruited to screening changes (for example, previously unscreened women are engaged), the rate may rise. The rate is also expected to be higher in certain years, due to the change in the screening interval from two years to five years: for example, women attending in 2020-2022 will either be overdue for screening or under surveillance, so the women attending for screening these years will be at higher risk, and there will also be far fewer of them21.
INDICATOR 4 – PREVALENCE OF HPV INFECTION

Rationale
The ability to achieve cervical cancer elimination is dependent upon the reduction in prevalence of oncogenic HPV types through HPV vaccination. Monitoring infection prevalence, in settings where this is feasible, provides a direct measure of the extent to which this reduction is being achieved and sustained over time.

Status of indicator
WHO target: no target set
Status: The prevalence of HPV16 or 18 in 2019 was very low, reflecting the success of Australia’s HPV vaccination program. Other oncogenic HPV types are commonly detected among screening participants, especially those in the youngest age groups.

In 2019, 2.0% of screening tests among women aged 25-74 years were positive for HPV16 or 18, the most oncogenic HPV types, which are prevented by both the quadrivalent and the more recent nonavalent HPV vaccines. Positivity was low across all socioeconomic groups, remoteness areas and jurisdictions. Positivity for oncogenic HPV types other than HPV16 or 18 was 6.5%, with higher positivity for women living in very remote areas, and women in the NT (Figure 4.1).

The additional five HPV types targeted by the nonavalent HPV vaccine (HPV31, 33, 45, 52 or 58) and the remaining HPV types not targeted by vaccination (HPV35, 39, 51, 56, 66 or 68) were detected among 4.3% and 6.3% of screening tests respectively, with little variation across socio-demographic characteristics (remoteness, jurisdiction and socioeconomic group) (Figure 4.2). HPV16 and HPV18 positivity was low, and relatively stable across age groups. In contrast, positivity for remaining oncogenic HPV types was highest among women aged 25–29 years and decreased with increasing age (Figure 4.3). These patterns reflect the population-level impact of Australia’s quadrivalent HPV vaccination program on reducing infection with HPV types 16 and 1822,23 while the impact of the nonavalent vaccine is yet to be seen because these cohorts are not yet at screening age.

Breakdowns by Indigenous status were not available.

Figure 4.1 – Oncogenic HPV positivity for women aged 25-74 years in 2019

Figure 4.2 – Positivity for nonavalent HPV vaccine-targeted and non-targeted oncogenic HPV types by socio-demographic characteristics for women aged 25-74 years in 2019 (rates from subset of national data from two HPV assays only)

Figure 4.3 – Positivity for HPV vaccine-targeted and non-targeted oncogenic HPV types by age groups for women aged 25-74 years in 2019 (rates from subset of national data for two HPV assays only)
DISEASE OUTCOME INDICATORS (Cont.)

Notes on methods
Source: AIHW, Cervical screening in Australia 2020 data, with additional analysis of NCSR data (NCSR RDE 3.4.0.25/09/2020) provided by AIHW.

Calculation of proportions in Figure 4.1 were based on national data reported to the NCSR. Data presented are based on the clinical management pathways of the NCSR: proportion of women with HPV16 and 18 (regardless of positivity for other types) versus proportion of women with other oncogenic types (in the absence of HPV16 and 18). Figure 4.2 and Figure 4.3 were derived from a small subset of results (n=34,000) from two assays that provided additional discrimination between vaccine-targeted and non-vaccine targeted HPV types. This group had similar overall HPV16 and 18 prevalence to the total national data albeit slightly lower (1.9% vs 2.0%). Results were derived using the standard method for calculating population prevalence: sum of women with individual genotyping data.

Interpretation, issues and challenges for this indicator
Many HPV vaccinated women have now attained the age at which they are participating in cervical screening. Linkage between the NCSR and AIR will in future permit comparisons of prevalence of HPV infection detected at screening between vaccinated and unvaccinated women. Surveys prior to the start of the vaccination program among women attending cervical screening suggested similar prevalence of HPV16/18 in Indigenous compared with non-Indigenous women at all ages, but a higher prevalence of other oncogenic types in middle age14. A survey conducted after the program had begun found declines in prevalence similar to those observed in non-Indigenous women, with an HPV16/18 prevalence among Indigenous women aged 16–26 of 1.4% in 2014–1515. A recent study of women 18–35 years found that the prevalence of HPV16/18 was very similar in Indigenous and non-Indigenous women (1.9% vs 1.6% respectively)16.

VACCINE COVERAGE INDICATORS

INDICATOR 5 – HPV VACCINE COMPLETION BY AGE 15 YEARS

Rationale
A high level of vaccine coverage sustained over many years, which will achieve population level control of vaccine targeted HPV types, is required in the long term for cervical cancer elimination15. For the purposes of monitoring coverage over time and comparing across countries, which vary in their age of vaccination within the range 9–14 years WHO recommends the use of the indicator ‘HPV vaccination coverage by age 15’18. This indicator measures the proportion of the population turning 15 in the reporting year who have completed their HPV vaccine course coverage by age 15, noting that the number of [correctly spaced] doses required to complete the course has changed over time from 3 doses to 2 doses.

The WHO target relates to female-only programs, which are the most cost-effective option. Australia has a both-sex program, and modelling suggests the same effect could be achieved with less than 90% coverage19.

Status of indicator

| WHO 2030 target: 90% of girls fully vaccinated by age 15 years |
| Status: HPV vaccination coverage with completed courses in both sexes was 78.2% (79.6% in females and 76.8% in males). |

Nationally, in the cohort who turned 15 in 2019, HPV vaccination coverage with completed courses was 78.2% (79.6% in females and 76.8% in males). Coverage of completed courses was substantially lower amongst Indigenous adolescents at 68.5% (female 71.6%, male 65.4%) than non-Indigenous (78.6% overall; female 80.0%, male 77.3%). (Figure 5.1). Completion coverage overall was over 80% in NSW (80.8%) and the ACT (81.2%) [data not shown], over 80% in females in NSW, Vic and ACT but no jurisdiction achieved over 80% completed course coverage in males (Figure 5.1). Completed HPV vaccine course coverage has increased between 2016 and 2019 in both sexes in both Indigenous and non-Indigenous adolescents (Figure 5.2).

Data on completed course coverage by remoteness and socioeconomic group were not available - see Indicator 6 initiation.

Notes on methods
Source: Australian Immunisation Register (AIR) data, sourced from NCIRS analysis as published in NCIRS 2021. Although the 2-dose schedule was not formally adopted until 2018, the 2019 cohort was the first to include some adolescents on a 2-dose schedule, due to early implementation of the schedule in NSW and a later average age of initiation in SA and WA. In the 2019 cohort, either two validly spaced doses (five months or more between doses) or three doses were considered to indicate course completion.

Interpretation, issues and challenges for this indicator
It should be noted that Australia has introduced both-sex vaccination and this provides additional herd immunity to non-vaccinated women (as has been well documented). Modelling has suggested, for countries that have introduced both-sex vaccination, that elimination of vaccine-preventable HPV types is likely achievable with a sustained coverage of 80%19. Additional investments into incremental improvements in vaccine coverage in Australia should therefore be supported by evidence of their cost-effectiveness. However, for countries that have not yet introduced or scaled up vaccination coverage, female-only vaccination is the most cost-effective option for achieving elimination; thus the 90% target has been set by WHO for female coverage and should be the first focus for those countries.

Coverage estimates from the former National HPV Vaccination Program Register had suggested that female three dose coverage had already exceeded 80%. HPV vaccine doses are now held in AIR and coverage is estimated using a different denominator (Medicare enrolments) which has resulted in slightly lower coverage estimates for the same cohorts20. It is too early to tell whether the move from a 3-dose to a 2-dose schedule has improved coverage. Any benefit might be diminished by the requirement that the second dose be administered at the same time as the previous third dose (6 months after the first); so completion may still be affected by factors such as higher school absenteeism in the second half of the school year.

Despite gradually improving coverage over time, a large disparity remains between Indigenous adolescents and non-Indigenous adolescents in receipt of the final dose.
VACCINE COVERAGE INDICATORS (Cont.)

Figure 5.1 – Completed HPV vaccine coverage by age 15 (2019 cohort)

Figure 5.2 – HPV vaccination completion by age 15 years (2016-2019)

INDICATOR 6 – HPV VACCINE INITIATION BY AGE 15 YEARS

Rationale

A high level of vaccine coverage sustained over many years, which will achieve population level control of vaccine targeted HPV types, is required in the long term for cervical cancer elimination2,27. For the purposes of monitoring coverage over time and comparing across countries, which vary in their age of vaccination within the range 9-14 years WHO recommends the use of the indicator ‘HPV vaccination coverage by age 15’28. This indicator measures the uptake of a first dose of HPV vaccine, rather than the completed course, to indicate acceptability of HPV vaccination. There is a growing body of evidence that one dose of HPV vaccine has substantial effectiveness20.

Status of indicator

WHO 2030 target: At least 90% of girls vaccinated (required to achieve 90% completion target)

Status: One dose coverage by age 15 in 2019 was 84.6% (female 85.7%, male 83.5%).

Nationally, in the cohort who turned 15 in 2019, HPV course initiation was 84.6%, at 85.7% in females and 83.5% in males. Both-sex one dose coverage was equivalent between Indigenous (84.0%) and non-Indigenous adolescents (84.6%). There was minimal variation by socioeconomic group or area of residence nationally (Figure 6.1). Three jurisdictions achieved over 90% HPV vaccine initiation amongst Indigenous females (NT 91.5%, NSW 90.7%, Vic 90.1%) (Figure 6.2). All groups nationally exceeded 80% HPV vaccine initiation although coverage in Indigenous males in the lowest quintile of socioeconomic group was just below (79.8%) (Figure 6.2). Between 2016 and 2019, HPV vaccine initiation has improved in both sexes in both Indigenous and non-Indigenous adolescents (Figure 6.3).
VACCINE COVERAGE INDICATORS (Cont.)

**Figure 6.2 – HPV vaccine initiation by age 15 years in 2019, Australia, by sex, Indigenous status, remoteness of residence and socioeconomic status**

**Figure 6.3 – HPV vaccination initiation by age 15 years (2016-2019)**

Notes on methods

Source: AIR data, sourced from NCIRS analysis as published in NCIRS 2021.

Interpretation, issues and challenges for this indicator

These data suggest slowly improving HPV vaccine initiation over time, although with some inequities and an ongoing disparity between female and male initiation. There is no explicit WHO 2030 or Australian target for HPV vaccine initiation although coverage over 90% for females is implied by the WHO 2030 90% completion target for girls-only programs. Modelling has suggested, for countries that have introduced both-sex vaccination, that elimination of vaccine-preventable HPV types is likely achievable with a sustained coverage of 80%10. Should one dose of HPV vaccine be proven to be effective, then the initiation rate achieved would become the completed coverage rate. Data presented are not directly comparable with historical estimates from the former National HPV Vaccination Program Register, which had suggested somewhat higher dose 1 coverage, due to change in the denominator population used.

It should be noted that this indicator is designed to monitor achievement of coverage by a certain age over time rather than highest coverage ever achieved in a birth cohort (for example, for the 2019 15 year old cohort by 31 Dec 2019 coverage was 86.2% and 84.1% in females and males respectively, compared to the 85.7% and 83.5% reported here, reflecting HPV vaccine doses given at age 15).
**SCREENING PARTICIPATION INDICATORS**

**INDICATOR 7 – SCREENING PARTICIPATION BY AGE 35 AND 45 YEARS**

### Rationale

Vaccination against HPV will take decades to reduce overall cervical cancer incidence, due to the time taken for vaccinated cohorts to reach the age at which they would have developed cancer and to make up a large enough proportion of the population to affect overall incidence rates. Cervical screening therefore is important to expedite elimination of cervical cancer10,11. The WHO strategy to accelerate the elimination of cervical cancer sets a target of screening women at least twice, at around age 35 and 45 years. Around half of the women diagnosed with cervical cancer in Australia had never been screened12, emphasising the importance of this indicator, even though more frequent screening is recommended in the NCSP.

Primary HPV screening has been recommended in Australia since 1st December 2017, not yet long enough for any women to have had a primary HPV test by age 35 and another by age 45. The second part of this indicator therefore reports on the proportion of women aged 45 who have been screened at least twice, including at least one primary HPV test and at least one cytology test prior to 1st December 2017 at least two years apart, as an interim measure.

### Status of indicator

**WHO 2030 target:** 70% of women screened using a high-performance test by age 35 years of age and again by 45 years of age.

**Status:** Nationally, 54.9% of women aged 35 had been screened at least once with an HPV test and 54.9% of women aged 45 had been screened at least twice, including at least once with an HPV test and one preceding cytology test within the previous 10 years (with at least two years spacing between the tests). Data are not yet available to report on this indicator for Indigenous women. In most areas of Australia, 50-60% of women met these indicators for screening uptake; however fewer than half of eligible women aged 35 and living in very remote areas had had at least one HPV test.

### Notes on methods

* Percent is age-standardised across women aged 25-74, using the Australia 2001 standard population13. ABS population estimates from14. Hysteroscopic prevalence from AIHW analysis of National Hospital Morbidity Database15. Compass participants adapted from16. Women who are eligible for screening comprise the estimated resident population, minus an estimate of the number of women who have had a hysterectomy and the number of women enrolled in the Compass trial, consistent with routine AIHW reports17,18,19,20. ABS data for estimated residential population are preliminary for 2019.

### Interpretation, issues and challenges for this indicator

This WHO indicator was designed to be a minimum target for low and lower-middle income countries and does not necessarily reflect the preferred approach for higher income countries. Being screened at least once substantially reduces a woman’s risk of cervical cancer10,21. Presentation of this indicator represents the first Australian data on the proportion of women ever-screened based on a national population-based data source. The WHO target for this measure was set for 2030, modelling used to inform the WHO targets assumed that screening uptake would scale up further after this time10,21. As Australia has a well-established screening program, it may reach the 2030 target and scale screening up earlier than other countries10,21.
SCREENING PARTICIPATION INDICATORS (Cont.)

INDICATOR 8 – SCREENING PARTICIPATION (AUSTRALIAN PROGRAM)

Rationale
Cervical screening is important to expedite elimination of cervical cancer, as HPV vaccination requires several decades to have its full effects across the population. As Australia has a well-established screening program with screening recommended more frequently than in the WHO elimination strategy\(^2\), the proportion of women screened according to recommended more frequently than in the WHO elimination has a well-established screening program with screening to have its full effects across the population. As Australia cervical cancer, as HPV vaccination requires several decades Cervical screening is important to expedite elimination of NCSR to allow reporting by Indigenous status. Given cervical cancer incidence rates are much higher among Indigenous women, and cervical screening is critical to reduce cervical cancer incidence in the nearer term, understanding and reporting screening coverage in Indigenous women is critical to achieving timely elimination among Indigenous women. There have been earlier studies of cervical screening coverage in Indigenous women, in the pre-renewed NCSP, based on analyses of ad hoc linked data for Qld, NSW, and the NT\(^7\), in all three of those jurisdictions, Indigenous women were less likely to have been screened in the previously recommended interval of two years, and over a longer interval of five years (data only reported for Qld and NSW).

Notes on methods
Source: AIHW analysis of NCSR data (NCSR RDE 3.4.0 25/09/2020), adapted from\(^3\). Percent is age-standardised across women aged 25-74, using the Australia 2001 standard population\(^1\). ABS population estimates from\(^3\).\(^4\). Hysterectomy prevalence from AIHW analysis of National Hospital Morbidity Database\(^5\). Compass participants adapted from\(^6\). Women who are eligible for screening comprise the estimated resident population, minus an estimate of the number of women who have had a hysterectomy and the number of women enrolled in the Compass trial, consistent with routine AIHW reports\(^7\).\(^8\).\(^9\).\(^10\).\(^11\).\(^12\).\(^13\).\(^14\).\(^15\). ABS data for estimated residential population are preliminary for 2019.

Status of indicator
The proportion of women 70-74 years; prior to this, 2-yearly cytology was recommended for women aged 20-69 years. Women were due to attend for their first HPV test two years after their last negative routine cytology test, or when they turned 25, whichever was later. Status: Nationally, 52.4% of eligible women were up to date with recommended screening in 2019. Data were not available to report on this measure for Indigenous women. Fewer than half of the eligible women living in the NT, in the middle quintile of socioeconomic disadvantage; or in outer regional, remote, or very remote areas, were up to date with recommended screening.

Data by Indigenous status was not available.

Data included in the current report were based on previous analyses by AIHW, and only include women with a test over the period 2018-2019, that is, women with a primary HPV test in December 2017 were not able to be included in the data used in the current report. Interpretation, issues and challenges for this indicator
Data on Indigenous status are not yet sufficiently complete on the NCSR to allow reporting by Indigenous status. Given cervical cancer incidence rates are much higher among Indigenous women, and cervical screening is critical to reduce cervical cancer incidence in the nearer term, understanding and reporting screening coverage in Indigenous women is critical to achieving timely elimination among Indigenous women. There have been earlier studies of cervical screening coverage in Indigenous women, in the pre-renewed NCSP, based on analyses of ad hoc linked data for Qld, NSW, and the NT\(^7\). In all three of those jurisdictions, Indigenous women were less likely to have been screened in the previously recommended interval of two years, and over a longer interval of five years (data only reported for Qld and NSW). Data included in the current report were based on previous analyses by AIHW, and only include women with a test over the period 2018-2019, that is, women with a primary HPV test in December 2017 were not able to be included in the data used in the current report. Therefore, our estimates will represent underestimates of women who are up to date with screening, as women with a primary HPV test in 2017 would still have been considered as up to date as at the end of 2019 (since their HPV test was within the previous five years). The effect of this is potentially small, as there are typically fewer tests in December than other months\(^7\). Additionally, data here only capture the first two years since primary HPV screening was recommended. As a result, the proportion of women who are up to date with screening is expected to naturally increase for the next few years (that is, over the first five years of the renewed NCSP), as more women attend for their first HPV test over time and are considered up to date, and no women who have had their first HPV test will become overdue until December 2022. Additionally, by 31st December 2019, all screen-eligible women would have been due to attend for their first HPV test; however, reminder letters had not yet been sent to all women who had not attended. Data from the cytology-based NCSP suggest that many women who do not attend within two years (the approximate time since transition) do eventually attend by three or five years, and reminders assist this\(^1\). The delay in implementation of the new national register’s full operations, including reminder services to under-screened women and the slow national scale up of self-collection as part of the program, could mean that measures aimed at decreasing inequity in screening participation had not yet achieved their full potential impact. The estimates here are not directly comparable with estimates in routine AIHW reports, as the estimates here encompass HPV tests performed for any purpose, and the denominator uses the estimated resident population as at mid-2019 (the most recent age-specific estimates available by geographic areas that allowed mapping to remoteness area and area-level socioeconomic status).
TREATMENT UPTAKE INDICATORS

INDICATOR 9 – COLPOSCOPY ATTENDANCE

Rationale
In Australia, assessment by colposcopic examination of the cervix is an integral part of the diagnostic pathway once a person is deemed to be at a sufficient underlying risk of a high-grade cervical abnormality through the screening process. Factors that may impact an individual’s ability to follow the screening pathway through to diagnostic assessment include whether they received and understand their screening result, understand the need for further assessment and are referred in a timely way, their ability to access colposcopy (service availability, cost, transport, time) and the acceptability of the procedure to that person. Australia’s cervical screening registries have long played a role as a safety net to support participant and clinician’s awareness of results requiring further follow up through systematic reminders and escalating alerts where the recommended pathway has not been followed. Assessment at colposcopy is necessary to identify lesions (via biopsy of suspicious areas) requiring treatment, for which assessment at colposcopy is necessary to identify lesions (via biopsy of suspicious areas) requiring treatment, for which

Breakdown by Indigenous status was not available.

Notes on methods
Source: AIHW, Cervical screening in Australia 2020 data, with additional analysis of NCSR data (NCSR RDE 1.40.450/2009) provided by AIHW.

The closest proxy available to assess whether a woman ever had a colposcopy was to include all data as at close of the available dataset, which allowed 15 months follow up for all women referred in 2018. Data presented are as per the methodology of the AIHW National Cervical Screening Program monitoring report 2020. Time to colposcopy is taken from the date of a person’s first higher risk screening episode.

Interpretation, issues and challenges for this indicator
Completeness of colposcopy data within the NCSR is unknown, with reports submitted by clinicians supplemented by the use of Medicare rebate data and biopsy/histology data to capture the fact of a colposcopy event (although colposcopy may also be used for other indications with no unique MBS code). Thus the estimates represent minimum values based on notifications to the NCSR. Only some higher risk groups have nationally stated targets for time to further assessment (being 2 weeks for women suspected to have cancer on reflex cytology and 8 weeks for HPV positive women with high-grade cytology) within the national guidelines, neither of which are explicitly separated in routine data. The available data suggest that many women may be experiencing suboptimal times to further assessment in this period of high colposcopy demand during transition to HPV based screening and from the 2-year to 5-year interval, but that prioritization of women by referral indication is occurring. Timely colposcopy attendance appears to vary by socioeconomic status and remoteness, which may relate to access barriers and service availability. This is of concern given that women residing in remote and very remote areas and who reside in areas of lower socioeconomic status are known to be at higher risk of cervical cancer (see indicator 1). The delay in implementation of the new national register’s full operations, including reminder services to support women to participate and complete follow up (which may be particularly important for those with significant barriers to attendance at care) could mean that existing inequities in screening participation and follow up have not decreased, and could in fact have increased given the increased demand on services in this period. Previous data from Queensland suggested that barriers to timely colposcopy follow up may impact Indigenous women to a greater extent than non-Indigenous women.
**TREATMENT UPTAKE INDICATORS (Cont.)**

**INDICATOR 10 – HIGH-GRADE CERVICAL DISEASE TREATMENT RATES**

**Rationale**
Cervical screening is important to expedite elimination of cervical cancer, as it will take decades for the impact of HPV vaccination to be reflected in overall cervical cancer incidence. For screening to prevent cervical cancer, treatment of screen-detected high-grade abnormalities is essential.

A target has been set in the WHO strategy to accelerate elimination of cervical cancer for treatment of women with identified disease.

**Status of indicator**

**Notes on methods**
High-grade abnormality is defined as HSIL NOS (S3.1), HSIL-CIN2 (S3.2), HSIL-CIN3 (S3.3), or AIS (E3.2, E3.3); a record of ablative or excisional treatment is identified through either colposcopy or histology records. Date of diagnosis is defined as the biopsy sample collection date and allows for treatment on the same date as biopsy.

This indicator will in future report on the proportion of women with a biopsy sample confirming a high-grade abnormality, who have a record of treatment within 8 weeks, 6 months, and 12 months of their diagnosis date.

**Interpretation, issues and challenges for this indicator**
 Routinely published data are not available for reporting against this WHO indicator, so reporting relies on additional data requests, and on sufficiently complete reporting and recording of histology and colposcopy data on the NCSR. Sufficiently complete data were not available for inclusion in this report. It is considered likely that most women do receive treatment for a biopsy proven high-grade abnormality in Australia, in the context of the registry infrastructure which provides a safety net to alert women and their clinicians where a recommended pathway has not been completed and national linked data showing that most cervical cancer occurs in never or under screened women.

The proportion of women treated will be reported for multiple timeframes. The 2030 WHO target does not stipulate a timeframe over which to measure whether treatment has occurred, so it is not clear to which of these timeframes the 90% target should apply. We will present results at multiple timepoints to enable better visibility of whether treatment does eventually occur (by 12 months) as well as whether it occurs in a shorter timeframe, more consistent with best practice (8 weeks, 6 months).

**WHO 2030 target:** 90% of women with identified precancer are treated.

**Status:** No routine data available to support this indicator.

It was not possible to obtain sufficiently complete data from the NCSR to report on this indicator in the current report. Routine NCSP monitoring reports do not include an indicator for treatment of high-grade abnormalities, so could not be used as an interim measure for this report.

**INDICATOR 11 – CERVICAL CANCER TREATMENT RATES**

**Rationale**
Management of invasive cervical cancer in accordance with accepted guidelines is important as the cervical cancer incidence nationally was 4.3 per 100,000 from 2011-2015 despite the national cervical screening program. With the full impact of HPV vaccination on cervical cancer incidence decades away, continued screening as well as optimal stage-appropriate treatment of cervical cancer remain vital to reduce the mortality from invasive cervical cancer.

**Status of indicator**

**WHO 2030 target:** Management of 90% of women with invasive cervical cancer.

**Status:** No routine national data available to support this indicator.

In Queensland, a Cancer Quality Index was developed to track progress in delivering safe, quality cancer care within health care services using State level linked data. Between the periods 2005-2009 and 2010-2014, age adjusted cervical cancer treatment rates (defined as at least one of hysterectomy, radiotherapy or chemotherapy) rose to over 90% regardless of area of residence. Treatment rates were stable for cervical cancer using hysterectomy and radiotherapy and rose for IV systemic therapy (chemotherapy). Whilst the proportion of cervical cancer patients receiving multidisciplinary team review rose considerably, the number of patients receiving treatment within 30 days of diagnosis fell from 39% to 30%. In the 2010-2014 period, there was a large disparity in the proportion of patients receiving treatment within 30 days by use of public vs private facilities but no differences by remoteness or older age. The rate of treatment within 30 days was 24% for all Indigenous patients, compared to 21% and 51% for Non-Indigenous patients treated in public and private hospitals respectively. There was no difference in the proportion of patients treated within 30 days by socioeconomic status in public hospitals but there was a gradient observed in private hospitals (Table 11.1). A study of 385 women undergoing first treatment for diagnosed cervical cancer; between 1999-2008 at the Royal Women’s Hospital (RWH), a tertiary referral centre in Melbourne, compared observed treatment rates with modelled optimal treatment rates. Optimal treatment was based on guidelines synthesised from local recommendations and international guidelines. As shown in Table 11.2, rates of surgery matched those predicted as the optimal rate, whereas rates of radiotherapy, chemotherapy and chemoradiotherapy were lower than predicted as optimal. A second study examined 105 women diagnosed with cervical cancer receiving care in public hospitals in Queensland between 1998-2004, to determine if being Indigenous and/or other factors were associated with receiving suboptimal care, based on local clinical guidelines. Indigenous women had seven times the odds of receiving suboptimal care than non-Indigenous women (unadjusted odds ratio OR 7.1, 95% confidence interval [CI] 1.5-33.3; OR 5.7, 95%CI 1.2-27.3 adjusted for stage) (Figure 11.1). Barriers for Indigenous women receiving gynaecological cancer care include difficulties accessing treatment, feeling disempowered, lack of culturally appropriate information, lack of financial and other supports, and cultural insensitivities.
Table 11.2 – The estimated percentage of patients with cervical cancer who should receive each treatment type according to the guidelines, compared with the observed rates from a pattern of care study at the Royal Women’s Hospital, Melbourne in 1999-200849

<table>
<thead>
<tr>
<th>FIGO stage**</th>
<th>Baseline % (95% credible interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Overall</td>
<td>Optimal rates</td>
</tr>
<tr>
<td>IA1</td>
<td>98 (96–100)</td>
</tr>
<tr>
<td>IA2</td>
<td>100 (95–100)</td>
</tr>
<tr>
<td>IB-Ia (Overall)</td>
<td>81 (77–85)</td>
</tr>
<tr>
<td>IB-Ia (&lt;4 cm)</td>
<td>100 (99–100)</td>
</tr>
<tr>
<td>IB-Ia (&gt;4 cm)</td>
<td>26 (27–34)</td>
</tr>
<tr>
<td>IB-IIa</td>
<td>0 (0–0)</td>
</tr>
<tr>
<td>IVB</td>
<td>0 (0–0)</td>
</tr>
</tbody>
</table>

** FIGO (International Federation of Gynecology and Obstetrics) stage refers to how far a cancer has spread at diagnosis. Stage I cancers are confined to the cervix, Stage 2 extend beyond the cervix but not into the pelvic wall, Stage 3 into the pelvic wall and Stage 4 beyond the pelvis. Details of current FIGO cervical cancer staging can be found in Bhatla et al 201853.

---

Table 11.1 – Selected measures from the Cancer Quality Index for women diagnosed with invasive cervical cancer, Queensland 2005-201447,48

<table>
<thead>
<tr>
<th>FIGO stage**</th>
<th>Baseline % (95% credible interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cervical cancer treatment rate*</td>
<td></td>
</tr>
<tr>
<td>Metropolitan</td>
<td>93%</td>
</tr>
<tr>
<td>Regional</td>
<td>86%</td>
</tr>
<tr>
<td>Rural and remote</td>
<td>89%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rate by treatment type</th>
<th>Optimal rates</th>
<th>Observed rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hysterectomy</td>
<td>37%</td>
<td>37%</td>
</tr>
<tr>
<td>(median length of stay 4 days)</td>
<td>(median length of stay 4 days)</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>72%</td>
<td>48%</td>
</tr>
<tr>
<td>IV systemic therapy</td>
<td>30%</td>
<td>40%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviewed by multidisciplinary team**</th>
</tr>
</thead>
<tbody>
<tr>
<td>2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Receipt of treatment within 30 days of diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>39%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By remoteness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metropolitan</td>
</tr>
<tr>
<td>Regional</td>
</tr>
<tr>
<td>Rural and remote</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By age</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;75 years</td>
</tr>
<tr>
<td>75 years or older</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By Indigenous status</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Indigenous</td>
</tr>
<tr>
<td>Non-Indigenous public hospital</td>
</tr>
<tr>
<td>Non-Indigenous private hospital</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By socioeconomic status***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public hospital</td>
</tr>
<tr>
<td>Disadvantaged</td>
</tr>
<tr>
<td>Middle</td>
</tr>
<tr>
<td>Affluent</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Private hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disadvantaged</td>
</tr>
<tr>
<td>Middle</td>
</tr>
<tr>
<td>Affluent</td>
</tr>
</tbody>
</table>

---

* At least one of hysterectomy, radiotherapy or systemic IV therapy (chemotherapy)
** Known to be incompletely captured
*** Lowest quintile labelled as disadvantaged, middle three quintiles as middle and highest quintile as affluent as per source report.

---

Figure 11.1 – Percentage of women who received suboptimal care in 105 women diagnosed with cervical cancer in Queensland between 1998-200450

---

TREATMENT UPTAKE INDICATORS (Cont.)
TREATMENT UPTAKE INDICATORS

NOTES ON METHODS

Source: There are no routinely published national data available reporting cervical cancer treatment rates. Therefore, data presented are from State level linked data (the Queensland Oncology Repository links patient data from the Queensland Cancer Registry, Queensland Hospital Admitted Data Collection, on surgery, radiation therapy, and IV systemic therapy and data collected from multidisciplinary team meetings primarily in the public sector) and two small, published studies.

INTERPRETATION, ISSUES AND CHALLENGES FOR THIS INDICATOR

Identification of suitable data sources and development of a methodology to routinely report treatment rates or ideally (as undertaken in the two in-depth studies detailed here) optimal care treatment rates, are now required in order for Australia to report against current practice and monitor against the WHO 2030 scale up indicator treatment.

Although it is likely that over 90% of cervical cancer patients in Australia receive treatment, and the Queensland data provide a notable precedent for both feasible methods and the importance of monitoring cancer care data, the available data suggests that it is not always optimal, and that there may be disparities in care for Indigenous women. Overall cervical cancer survival data for Australia show minor improvements over time, rising between the periods 1986-1990 and 2011-2015 from 69.5% to 73.5%.

5-year relative survival. Australian survival is in the higher range of international benchmarks, which generally show a range in 5-year survival between 50-70%43. However, notably, consistent with the treatment data reported here, survival data also show disparities by Indigenous status, socioeconomic status and remoteness, which may be partially explained by diagnosis at a later stage44-46. Access to treatment and to culturally appropriate treatment may be substantial barriers for some patients47. It is unknown how many patients in Australia currently receive cervical cancer care in a tertiary referral centre or according to the optimal care pathway for cervical cancer which includes care informed by a multidisciplinary team.

WHilst some tertiary gynaecology centres do routinely publish numbers of cervical cancer patients seen, stage, demographics and some quality indicators48-50,51, particular challenges in developing a national method for monitoring cervical treatment rates and proportion receiving optimal care include:

1. Lack of collection of consistent staging information across cancer registries at a State and Territory level and delay in national cancer incidence data reporting

2. Lack of explicit national level guidelines for the treatment of cervical cancer against which to determine if optimal treatment by stage is being received

3. Lack of availability of existing national and State level linked data sets to map optimal care pathways against including cancer registry data, hospitalisation data, primary care data, palliative care data, MBS/PBS data, and radiotherapy data

Encouragingly the National Gynae-Oncology Registry, a clinical quality registry (https://ngcr.org.au), is aiming to eventually invite all newly diagnosed cervical cancer patients to participate and may, in doing so, overcome many of the key barriers identified above. This initiative may help facilitate the development of a high-quality measure to monitor cervical cancer treatment over time. Such a measure is required in order to identify and address any deficiencies and ensure optimal care is delivered equitably to cervical cancer patients across Australia.

REFERENCES


THE PATHWAY TO CERVICAL CANCER ELIMINATION IN AUSTRALIA

1989
VCS created Australia’s first cervical screening register

1991
Australia introduces National Cervical Screening Program
Ian Frazer and Jian Zhao co-discovered the particle that makes HPV vaccine possible

1991
VCS Foundation, Cancer Council NSW, Australian Federal Government, World Health Organization

2006
Ian Frazer Australian of the Year for role in discovery of HPV vaccines

2008
HPV Vaccination Program Register established by VCS

2007
Australia first to introduce a national HPV vaccination program
Routine school-based vaccination of adolescent girls; two-year catch up all women aged up to 26 years through GP

2009
Research: Australian world first data shows a decline in genital warts

2010
Research: Published in Lancet Public Health Cervical Cancer likely to be eliminated in Australia within 20 years

2011
Research: Australian world first data shows a decline in precancerous cervical abnormalities

2012
Research: Australian world first data shows a decline in HPV infections

2013
Australia introduced vaccination for adolescent males

2014
Research: Precancerous abnormalities have now dropped by 41% nationally in women aged 20-24 years
Evidence shows strong impact of HPV vaccination across all Australian women including indigenous women

2017
Research: Evidence demonstrates that primary HPV screening is more effective than cytology in Australia
NCSP shifts to HPV-based primary screening and introduces self-collection

2018
Next generation nonavalent vaccine was introduced
Australian Immunisation Register incorporates HPV vaccination data from VCS
HPV register

2019
Research: Published in Lancet Public Health Cervical Cancer likely to be eliminated in Australia within 20 years

2020
World Health Organization launches global strategy for the elimination of cervical cancer as a public health problem. Australia played a key role in the development of the strategy.

2021
Research: Australia could benefit by expanding the availability of HPV testing by self-collected sample within the NSCP